Phillip Pang - Jul 21, 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Medical Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Stock symbol: VIR
Transactions as of: Jul 21, 2021
Transactions value $: -$166,055
Form type: 4
Date filed: 7/23/2021, 05:00 PM
Previous filing: Jul 8, 2021
Next filing: Aug 5, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Options Exercise	$7.29K	+4.63K	+4.24%	$1.58^*	114K	Jul 21, 2021	Direct
transaction	VIR	Common Stock	Sale	-$173K	-4.63K	-4.06%	$37.44	109K	Jul 21, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Options Exercise	$0	-4.63K	-9.52%	$0.00	44K	Jul 21, 2021	Common Stock	4.63K	$1.58	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.12 to $37.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.